MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
uniQure N.V. Operating Income 2011-2026 | QURE
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income uniQure N.V.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -184 M | -283 M | -143 M | 311 M | -125 M | -121 M | -88.2 M | -71.3 M | -71.9 M | -71.2 M | -53.7 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 311 M | -283 M | -82.1 M |
Quarterly Operating Income uniQure N.V.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -51 M | -43.9 M | -39.3 M | - | -40.2 M | -44 M | -54.2 M | - | -81.9 M | -65.1 M | -74.2 M | - | -59.5 M | -56.1 M | -54.1 M | - | -45 M | 398 M | -44.5 M | - | -44.5 M | -38.2 M | -34.5 M | - | -31.3 M | -29.3 M | -27.5 M | - | -23.2 M | -21.2 M | -19.6 M | - | -9.28 M | -19.7 M | -19.7 M | - | -14.2 M | -22.1 M | -19.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 398 M | -81.9 M | -24.3 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
Adagene
ADAG
|
-36 M | $ 1.9 | -3.11 % | $ 107 M |  China |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K |  USA |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
205 M | $ 25.88 | -0.73 % | $ 1.25 B | USA |
 |
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.7 | 1.5 % | $ 17 M | USA |
 |
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-209 M | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-24.8 M | $ 2.9 | 0.52 % | $ 908 M |  Israel |
 |
BeiGene, Ltd.
BGNE
|
-568 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
BioNTech SE
BNTX
|
15.3 B | $ 106.07 | -2.69 % | $ 27.2 B | Germany |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.13 M | $ 3.96 | -1.0 % | $ 8.62 B | Israel |
 |
CASI Pharmaceuticals
CASI
|
-41.8 M | $ 0.95 | -0.72 % | $ 129 M | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 215.17 | 4.54 % | $ 5 B |  Danmark |
 |
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Bio-Path Holdings
BPTH
|
-15.8 M | - | - | $ 100 K | USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Baudax Bio
BXRX
|
-56.8 M | - | 0.59 % | $ 63 K | USA |
 |
Celldex Therapeutics
CLDX
|
-195 M | $ 25.17 | -1.89 % | $ 1.62 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
98.3 M | $ 64.51 | 1.04 % | $ 8.63 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
195 M | $ 23.24 | 2.38 % | $ 2.75 B | USA |
 |
Burford Capital Limited
BUR
|
242 M | $ 9.65 | -0.72 % | $ 1.56 B | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
-140 M | - | -15.15 % | $ 60.3 M | Britain |
 |
AIkido Pharma
AIKI
|
-11.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-58.1 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Catalyst Biosciences
CBIO
|
-67.2 M | $ 14.0 | 3.63 % | $ 922 M | USA |
 |
Biogen
BIIB
|
7.04 B | $ 164.49 | 0.04 % | $ 23.9 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Avid Bioservices
CDMO
|
-18.7 M | - | - | $ 789 M | USA |
 |
BioVie
BIVI
|
-18.1 M | $ 1.24 | 2.49 % | $ 1.83 M | USA |
 |
Calithera Biosciences
CALA
|
-115 M | - | -10.95 % | $ 876 K | USA |